Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?
Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?
PURPOSE:
Clinical and observational studies suggest that use of thiazolidinediones (TZDs) is associated with an increased fracture risk. In addition, type 2 diabetes mellitus (T2DM) is a risk factor for osteoporotic fracture. Our aim was to estimate fracture risks in TZD users and users of other antidiabetic drugs, classified according to proxies of disease severity.
METHODS:
We conducted a population-based cohort study utilizing the Dutch PHARMO database (1998-2008). PHARMO links pharmacy-dispensing data to the National Hospital Registry. Oral antidiabetic users (n = 123,452) were matched 1:4 by year of birth and sex to non-users. Cox proportional hazards models were used to estimate hazard ratios (HRs) of fracture in TZD users. We created a proxy indicator for disease severity. The first stage was defined as current use of either a biguanide or a sulfonylureum, the second stage as current use of a biguanide and a sulfonylureum at the same time, the third stage was assigned to patients using TZDs and the fourth stage to patients using insulin.
RESULTS:
The risk of osteoporotic fracture was increased 1.5-fold (HR 1.49, 95%CI 1.28-1.73) in patients who currently used TZDs (stage 3), and for patients using insulin (stage 4), the risk was increased 1.2-fold (HR 1.24, 1.14-1.36), as compared with controls. In the first and second stages, risks were lower: HR 1.11 (1.06-1.17) for stage 1 and HR 1.03 (0.96-1.11) for stage 2.
CONCLUSIONS:
When observational studies assess risk of fracture in patients with TZDs, the severity of T2DM should be taken into account.
thiazolidinediones, type 2 diabetes mellitus, fracture risk, osteoporosis, adverse events
507-514
Bazelier, Marloes T.
701385a8-2cb1-4258-88a4-249c3a7f07f5
Gallagher, Arlene M.
4a77b2c1-c628-47e0-a29c-f726ca3445bc
van Staa, Tjeerd-Pieter
f840d545-0e8d-40fe-9124-976826190cc3
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Leufkens, Hubert G. M.
3c6f2841-6825-4de0-b967-1d4aa5498a5d
Vestergaard, Peter
3336d4f1-072c-4b02-935e-a5eca05858e2
de Vries, Frank
10245a32-6083-4feb-9d20-7e7db0f358b1
May 2012
Bazelier, Marloes T.
701385a8-2cb1-4258-88a4-249c3a7f07f5
Gallagher, Arlene M.
4a77b2c1-c628-47e0-a29c-f726ca3445bc
van Staa, Tjeerd-Pieter
f840d545-0e8d-40fe-9124-976826190cc3
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Leufkens, Hubert G. M.
3c6f2841-6825-4de0-b967-1d4aa5498a5d
Vestergaard, Peter
3336d4f1-072c-4b02-935e-a5eca05858e2
de Vries, Frank
10245a32-6083-4feb-9d20-7e7db0f358b1
Bazelier, Marloes T., Gallagher, Arlene M., van Staa, Tjeerd-Pieter, Cooper, Cyrus, Leufkens, Hubert G. M., Vestergaard, Peter and de Vries, Frank
(2012)
Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?
Pharmacoepidemiology and Drug Safety, 21 (5), .
(doi:10.1002/pds.3234).
(PMID:22392882)
Abstract
PURPOSE:
Clinical and observational studies suggest that use of thiazolidinediones (TZDs) is associated with an increased fracture risk. In addition, type 2 diabetes mellitus (T2DM) is a risk factor for osteoporotic fracture. Our aim was to estimate fracture risks in TZD users and users of other antidiabetic drugs, classified according to proxies of disease severity.
METHODS:
We conducted a population-based cohort study utilizing the Dutch PHARMO database (1998-2008). PHARMO links pharmacy-dispensing data to the National Hospital Registry. Oral antidiabetic users (n = 123,452) were matched 1:4 by year of birth and sex to non-users. Cox proportional hazards models were used to estimate hazard ratios (HRs) of fracture in TZD users. We created a proxy indicator for disease severity. The first stage was defined as current use of either a biguanide or a sulfonylureum, the second stage as current use of a biguanide and a sulfonylureum at the same time, the third stage was assigned to patients using TZDs and the fourth stage to patients using insulin.
RESULTS:
The risk of osteoporotic fracture was increased 1.5-fold (HR 1.49, 95%CI 1.28-1.73) in patients who currently used TZDs (stage 3), and for patients using insulin (stage 4), the risk was increased 1.2-fold (HR 1.24, 1.14-1.36), as compared with controls. In the first and second stages, risks were lower: HR 1.11 (1.06-1.17) for stage 1 and HR 1.03 (0.96-1.11) for stage 2.
CONCLUSIONS:
When observational studies assess risk of fracture in patients with TZDs, the severity of T2DM should be taken into account.
This record has no associated files available for download.
More information
e-pub ahead of print date: 6 March 2012
Published date: May 2012
Keywords:
thiazolidinediones, type 2 diabetes mellitus, fracture risk, osteoporosis, adverse events
Organisations:
Faculty of Health Sciences
Identifiers
Local EPrints ID: 340341
URI: http://eprints.soton.ac.uk/id/eprint/340341
ISSN: 1053-8569
PURE UUID: 70b938d4-f816-48ed-a30f-4e3367b78dcc
Catalogue record
Date deposited: 19 Jun 2012 15:24
Last modified: 18 Mar 2024 02:45
Export record
Altmetrics
Contributors
Author:
Marloes T. Bazelier
Author:
Arlene M. Gallagher
Author:
Tjeerd-Pieter van Staa
Author:
Hubert G. M. Leufkens
Author:
Peter Vestergaard
Author:
Frank de Vries
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics